id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
cord-269776-hj1s3ipp	Agostoni, Angelo	Hereditary and acquired angioedema: Problems and progress: Proceedings of the third C1 esterase inhibitor deficiency workshop and beyond	2004-09-11		.txt	text/plain	50588	2202	41	The plasma kallikrein-kinin system counterbalances the renin-angiotensin system The physiologic basis of assembly and activation of the plasma kallikrein/kinin system Mechanism of enhanced kinin release from high molecular weight kininogen by plasma kallikrein after its exposure to plasmin Detection of active kallikrein in induced blister fluids of hereditary angioedema patients Dose-dependent effects of postmenopausal estrogen and progestin on antithrombin III and factor XII Increased euglobulin fibrinolytic potential in women on oral contraceptives low in oestrogen-levels of extrinsic and intrinsic plasminogen activators, prekallikrein, factor XII, and C1-inactivator Molecular basis of estrogen regulation of Hageman factor XII gene expression Contact factors in plasma from women on oral contraception-significance of factor XI for the measured activity of factor XII Biochemical and molecular pharmacology of kinin receptors Transcription factor nuclear factor kappaB regulates the inducible expression of the human B1 receptor gene in inflammation Receptors for kinins: from classical pharmacology to molecular biology Mechanisms regulating the expression, self-maintenance, and signaling-function of the bradykinin B2 and B1 receptors Regulation of bradykinin B2-receptor expression by oestrogen Coexistence of hereditary angioedema and Turner's syndrome Hereditary angioedema precipitated by estrogen replacement therapy in a menopausal woman Recurrent episodes of skin angioedema and severe attacks of abdominal pain induced by oral contraceptives or hormone replacement therapy Recurrent angioedema: familial and oestrogen-induced Angioedema and oral contraception Recurrent angioedema associated with hypogonadism or anti-androgen therapy Estrogen induction and contact phase activation of human factor XII Enhanced expression of factor XII (Hageman factor) in isolated livers of estrogenand prolactin-treated rats The influence of estrogen and prolactin on Hageman factor (factor XII) titer in ovariectomized and hypophysectomized rats Differential regulation of kininogen gene expression by estrogen and progesterone in vivo The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives Effects of a very low-estrogen oral contraceptive on clotting factors, carbohydrate metabolism and plasma lipids and lipoproteins Contact activation factors in plasma from women using oral contraceptives-increased levels of factor XII, kinin-free high molecular weight kininogen and acetone-activated kallikrein Estrogen-associated thromboembolism Contact factor mediated fibrinolysis is increased by the combined oral contraceptive pill Prospective randomized study of effects of unopposed estrogen replacement therapy on markers of coagulation and inflammation in postmenopausal women Positive impact of hormone replacement therapy on the fibrinolytic system: a long-term randomized controlled study in healthy postmenopausal women Postmenopausal hormone replacement therapy increases coagulation activity and fibrinolysis Effect of long-term hormone replacement therapy on angiotensin-converting enzyme activity and bradykinin in postmenopausal women with essential hypertension and normotensive postmenopausal women Estrogen regulation of angiotensin-converting enzyme mRNA Sex hormones in hereditary angioneurotic oedema The complete drug reference Bethesda: American Society of Health-System Pharmacists DRUGDEXÒ system Hereditary angioedema and oral contraception Effects of methylamine and heparin on a rapid chromogenic assay of C1-esterase inhibitor in plasma Effect of time, temperature and additives on a functional assay of C1 inhibitor Effects of estrogen replacement therapy on the renin-angiotensin system in postmenopausal women Management and diagnostic guidelines for urticaria and angio-oedema Hereditary angioneurotic oedema in three families: symptomatic heterogeneity, complement analysis and therapeutic trials Hereditary angioneurotic oedema in Finland: clinical, immunological and genealogical studies Hereditary angioedema due to deficit of C1 esterase inhibitor Hereditary angioneurotic edema: a clinical survey C1-INH defect as an example of deficiency disease Hereditary angioedema: danazol therapy in a 5-year-old child Hereditary angioneurotic oedema: current management in pregnancy A multicentre evaluation of the diagnostic efficiency of serological investigations for C1 inhibitor deficiency Inherited and acquired deficiencies of C1 esterase inhibitor in humans C3 is activated in hereditary angioedema, and C1/C1-inhibitor complexes rise during physical stress in untreated patients Contact system in healthy term newborns: reference values in cord blood Application of a monoclonal antibody against a neoepitope on activated C4 in an ELISA for the quantification of complement activation via the classical pathway C1 inhibitor and diagnosis of hereditary angioedema in newborns Complement components in 100 newborns and their mothers determined by electroimmunoassay Angioedema: a review on the acquired, allergic or non-allergic, and the hereditary forms Serum complement levels in infancy: age related changes Influence of age and sex on serum complement components in children Development of the human coagulation system in the full-term infant Plasma protease inhibitors in premature infants: influence of gestational age, postnatal age, and health status Serum complement profiles in infants and children Misdiagnosis of hereditary angio-oedema type 1 and type 2 Acute consumption of C1 inhibitor in a patient with acquired C1-inhibitor deficiency syndrome Normal complement C4 values do not exclude hereditary angioedema Hereditary angioneurotic oedema Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate Replacement therapy in hereditary angioedema: successful treatment of acute episodes of angioedema with partly purified C1 inhibitor C1 INH concentrate in the therapy of hereditary angioedema C1-esterase inhibitor transfusions in patients with hereditary angioedema Replacement therapy in hereditary angioedema: successful treatment of two patients with fresh frozen plasma C1-inhibitor deficiency and angioedema Treatment of hereditary angioedema Letter: anaphylactic reaction to aprotinin DX-88 and HAE: a developmental perspective The synthetic Kunitz domain protein DX-88 to treat angioedema in patients with hereditary angioedema Role of kinins in seasonal allergic rhinitis: icatibant, a bradykinin B2 receptor antagonist, abolishes the hyperresponsiveness and nasal eosinophilia induced by antigen Efficacy and tolerability of Icatibant (Hoe 140) in patients with moderately severe chronic bronchial asthma Jerini announces positive phase II study results with Icatibant for the treatment of Hereditary Angioedema A phase I study of recombinant human C1-INH in asymptomatic patients with hereditary angioedema-HAE Pharming features clinical results of C1 inhibitor at investigator meeting [press release Treatment of hereditary angioedema with danazol: reversal of clinical and biochemical abnormalities Morphologic evaluation of the liver in hereditary angioedema patients on long-term treatment with androgen derivatives Side effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients The long-term safety of danazol in women with hereditary angioedema Long-term treatment of hereditary angioedema with attenuated androgens: a survey of a 13-year experience Danazol therapy: an unusual aetiology of hepatocellular carcinoma Hepatocellular adenomas in patients taking danazol for hereditary angio-oedema Danazol-induced hepatocellular adenoma in patients with hereditary angio-oedema A case of hereditary angioneurotic oedema, successfully treated with epsilonaminocaproic acid: studies on C'1 esterase inhibitor, C'1 activation, plasminogen level and histamine metabolism Long-term prophylaxis with C1-inhibitor (C1 INH) concentrate in patients with recurrent angioedema caused by hereditary and acquired C1-inhibitor deficiency Pharmacokinetic parameters of C1-inhibitor concentrate in 40 patients with hereditary angio-oedema (HAE)-a prospective study Acute airway obstruction following tooth extraction in hereditary angioedema Oral manifestations and dental management of patients with hereditary angioedema Hereditary angioedema: report of case Prophylactic use of epsilon aminocaproic acid for oral surgery in a patient with hereditary angioneurotic edema Tranexamic acid: preoperative prophylactic therapy for patients with hereditary angioneurotic edema Intravenous tranexamic acid in the management of hereditary angio-oedema Potentially fatal hereditary angioedema: a review and case report The efficacy of short-term danazol prophylaxis in hereditary angioedema patients undergoing maxillofacial and dental procedures Successful off-pump coronary artery bypass graft surgery in a patient with hereditary angioedema Preoperative prophylaxis for C1 esterase-inhibitor deficiency in patients undergoing oral surgery: a report of three cases Hereditary angioedema: uncomplicated maxillofacial surgery using short-term C1 inhibitor replacement therapy C1-esterase inhibitor concentrate prevents upper airway obstruction in hereditary angio-oedema Acquired angioedema as the presenting feature of lymphoproliferative disorders of mature B-lymphocytes Spontaneous regression of acquired C1 esterase inhibitor deficiency associated with splenic marginal zone lymphoma presenting with recurrent angio-oedema Acquired angioedema associated with rectal carcinoma and its response to danazol therapy: acquired angioedema treated with danazol Activation of the contact system and fibrinolysis in autoimmune acquired angioedema: a rationale for prophylactic use of tranexamic acid Angioneurotic edema with acquired C1-inhibitor deficiency and autoantibody to C1-inhibitor: response to plasmapheresis and cytotoxic therapy Purity, activity, and virus safety of a pasteurized antithrombin concentrate A factor VIII concentrate, highly purified and heated in solution Virus-safe plasma proteins: elimination of viruses of risk by the manufacturing procedure Inactivation of hepatitis A virus by pasteurization and elimination of picornaviruses during manufacture of factor VIII concentrate Absence of anti-human immunodeficiency virus types 1 and 2 seroconversion after the treatment of hemophilia A or von Willebrand's disease with pasteurized factor VIII concentrate Absence of hepatitis after treatment with a pasteurized factor VIII concentrate in patients with hemophilia and no previous transfusions Effectiveness of alternative treatments for reducing potential viral contaminants from plasma-derived products Inactivation of parvovirus B19 during pasteurization of human serum albumin A novel coronavirus associated with severe acute respiratory syndrome Virus safety of pasteurized clotting factor concentrates: an eleven year follow up Hepatitis C and pasteurized C1-inhibitor concentrate Prospective virus safety follow-up after therapy with a pasteurized C1-inhibitor concentrate Prophylactic treatment with pasteurised C1 inhibitor in herditary angioedema (HAE)-a prospective 32 months follow up Prospective follow up of clinical manifestation and therapy in children with hereditary angioedema (HAE) High-titer screening PCR: a successful strategy for reducing the parvovirus B19 load in plasma pools for fractionation Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin State of care for hemophilia in pediatric patients Hereditary angioedema Treatment of acute attacks of hereditary angioedema with C1-inhibitor concentrate Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency Proteolytic inactivation of plasma C1-inhibitor in sepsis Expression of active human C1 inhibitor serpin domain in Escherichia coli N-and O-glycans of recombinant human C1 Inhibitor expressed in the milk of transgenic rabbits Production of complex human glycoproteins in yeast Recombinant human C1-inhibitor produced in Pichia pastoris has the same inhibitory capacity as plasma C1-inhibitor Recombinant human C1-inhibitor produced in Pichia pastoris has the same inhibitory capacity as plasma C1-inhibitor Recombinant C1 inhibitor P5/P3 variants display resistance to catalytic inactivation by stimulated neutrophils The effect of danazol in the treatment of chronic cystic mastitis Danazol-induced pseudomenopause in the management of endometriosis Effects of danazol on pulsatile gonadotropin patterns and on serum estradiol levels in normally cycling women Cortical and trabecular bone mineral content in women with endometriosis: effect of gonadotropin-releasing hormone agonist and danazol A comparison of the skeletal effects of goserelin and danazol in premenopausal women with endometriosis Evidence of similar increases in bone turnover during nafarelin and danazol use in women with endometriosis Amino acids mutated in HAE patients are depicted in yellow ball-and-stick.	cache/cord-269776-hj1s3ipp.txt	txt/cord-269776-hj1s3ipp.txt
